Clinical Trial Update: Apixaban for Secondary Prevention of Thromboembolism Among Patients With AntiphosPholipid Syndrome [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating apixaban for secondary prevention of thromboembolism in patients with antiphospholipid syndrome has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Antiphospholipid Syndrome
• Thrombosis

Drugs mentioned

• Apixaban (apixaban)

Snippet

Sponsor: Scott C. Woller, MD | Conditions: Antiphospholipid Syndrome, Thrombosis | Phase 4 | Status: COMPLETED